XNASVIR
Market cap1.01bUSD
Dec 23, Last price
7.34USD
1D
0.00%
1Q
-2.65%
IPO
-46.77%
Name
Vir Biotechnology Inc
Chart & Performance
P/E
—
P/S
11.73
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
6.72%
Rev. gr., 5y
150.83%
Revenues
86m
-94.55%
Net income
-615m
L
CFO
-779m
L
Earnings
Feb 20, 2025
Profile
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||
Revenues | 86,180 -94.55% | 1,580,472 45.39% | 1,087,068 1,516.58% | ||||
Cost of revenue | 592,436 | 620,967 | 513,871 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (506,256) | 959,505 | 573,197 | ||||
NOPBT Margin | 60.71% | 52.73% | |||||
Operating Taxes | (13,077) | 238,443 | 21,218 | ||||
Tax Rate | 24.85% | 3.70% | |||||
NOPAT | (493,179) | 721,062 | 551,979 | ||||
Net income | (615,061) -219.24% | 515,837 -2.41% | 528,584 -276.98% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 7,767 | 39,440 | 100,590 | ||||
BB yield | -0.58% | -1.16% | -1.80% | ||||
| Debt | |||||||
Debt current | 12,867 | 4,137 | 3,927 | ||||
Long-term debt | 223,346 | 247,674 | 267,122 | ||||
Deferred revenue | 1,526 | 53,207 | 3,815 | ||||
Other long-term liabilities | 40,218 | 32,799 | 25,362 | ||||
Net debt | (1,391,471) | (2,174,156) | (638,484) | ||||
| Cash flow | |||||||
Cash from operating activities | (778,785) | 1,663,253 | (47,589) | ||||
CAPEX | (21,573) | (68,028) | (21,817) | ||||
Cash from investing activities | 164,629 | (1,193,461) | (140,814) | ||||
Cash from financing activities | 7,480 | 34,761 | 100,331 | ||||
FCF | (472,213) | 1,180,311 | (15,543) | ||||
| Balance | |||||||
Cash | 1,522,409 | 2,402,040 | 708,145 | ||||
Long term investments | 105,275 | 23,927 | 201,388 | ||||
Excess cash | 1,623,375 | 2,346,943 | 855,180 | ||||
Stockholders' equity | (238,626) | 368,128 | (139,686) | ||||
Invested Capital | 1,995,146 | 1,908,587 | 1,731,983 | ||||
ROIC | 39.61% | 34.28% | |||||
ROCE | 42.08% | 35.59% | |||||
| EV | |||||||
Common stock shares outstanding | 134,131 | 134,811 | 133,437 | ||||
Price | 10.06 -60.25% | 25.31 -39.55% | 41.87 56.35% | ||||
Market cap | 1,349,357 -60.45% | 3,412,064 -38.93% | 5,587,012 75.08% | ||||
EV | (42,114) | 1,237,908 | 4,948,528 | ||||
EBITDA | (486,805) | 966,288 | 579,008 | ||||
EV/EBITDA | 0.09 | 1.28 | 8.55 | ||||
Interest | 183,145 | ||||||
Interest/NOPBT | 19.09% | ||||||